BioCentury | Apr 6, 2019
Finance

Big caps under pressure

...Tokyo:4552) Remestemcel-L Treat steroid-refractory acute graft versus host disease (aGVHD) in children Submit BLA 2Q19 Mission Pharmacal Co....
BioCentury | Oct 6, 2018
Finance

Seeking validation

...Group / Eurofarma Laboratorios S.A. Baxdela delafloxacin Community-acquired bacterial pneumonia (CABP) Ph III data 4Q18 Mission Pharmacal Co....
BioCentury | Oct 19, 2015
Company News

Dara BioSciences, Onxeo sales and marketing update

...U.S. rights to the mucoadhesive buccal tablet of miconazole from Onxeo. Dara also partnered with Mission Pharmacal Co....
BioCentury | Jul 27, 2015
Company News

ProSolus, Mission Pharmacal deal

...Mission declined to disclose the terms of the acquisition. ProSolus Pharmaceuticals L.P. , Miami, Fla. Mission Pharmacal Co....
BioCentury | Mar 16, 2015
Company News

Onxeo, Dara BioSciences deal

...provide for an expanded indication. Onxeo considered Oravig a non-strategic drug. Dara also partnered with Mission Pharmacal Co....
BioCentury | Jun 9, 2014
Company News

Mission Pharmacal, Retrophin Inc. sales and marketing update

...particularly renal disease. Mission declined to disclose financial details, and Retrophin could not be reached. Mission Pharmacal Co....
BioCentury | May 19, 2014
Company News

Dara BioSciences sales and marketing update

...Group (Lugano, Switzerland). In 2013, Dara partnered with the Mission's Alamo Pharma Services subsidiary of Mission Pharmacal Co....
BioCentury | Mar 24, 2014
Company News

Meda, Mission Pharmacal sales and marketing update

...Antares is eligible for royalties (see BioCentury, Oct. 22, 2012). Meda AB (SSE:MEDAA), Solna, Sweden Mission Pharmacal Co....
BioCentury | Nov 4, 2013
Company News

Dara BioSciences, Mission Pharmacal sales and marketing update

...Feb. 18, 2013 & April 30, 2013). Dara Biosciences Inc. (NASDAQ: DARA ), Raleigh, N.C. Mission Pharmacal Co....
BioCentury | Jan 7, 2013
Finance

Buyside View XXI: Sunny side up

...Laboratories Inc. (NASDAQ:DSCO) Surfaxin lucinactant Prevent respiratory distress syndrome in premature infants U.S. EffRx Pharmaceuticals S.A./Mission Pharmacal Co./...
Items per page:
1 - 10 of 17
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

...Tokyo:4552) Remestemcel-L Treat steroid-refractory acute graft versus host disease (aGVHD) in children Submit BLA 2Q19 Mission Pharmacal Co....
BioCentury | Oct 6, 2018
Finance

Seeking validation

...Group / Eurofarma Laboratorios S.A. Baxdela delafloxacin Community-acquired bacterial pneumonia (CABP) Ph III data 4Q18 Mission Pharmacal Co....
BioCentury | Oct 19, 2015
Company News

Dara BioSciences, Onxeo sales and marketing update

...U.S. rights to the mucoadhesive buccal tablet of miconazole from Onxeo. Dara also partnered with Mission Pharmacal Co....
BioCentury | Jul 27, 2015
Company News

ProSolus, Mission Pharmacal deal

...Mission declined to disclose the terms of the acquisition. ProSolus Pharmaceuticals L.P. , Miami, Fla. Mission Pharmacal Co....
BioCentury | Mar 16, 2015
Company News

Onxeo, Dara BioSciences deal

...provide for an expanded indication. Onxeo considered Oravig a non-strategic drug. Dara also partnered with Mission Pharmacal Co....
BioCentury | Jun 9, 2014
Company News

Mission Pharmacal, Retrophin Inc. sales and marketing update

...particularly renal disease. Mission declined to disclose financial details, and Retrophin could not be reached. Mission Pharmacal Co....
BioCentury | May 19, 2014
Company News

Dara BioSciences sales and marketing update

...Group (Lugano, Switzerland). In 2013, Dara partnered with the Mission's Alamo Pharma Services subsidiary of Mission Pharmacal Co....
BioCentury | Mar 24, 2014
Company News

Meda, Mission Pharmacal sales and marketing update

...Antares is eligible for royalties (see BioCentury, Oct. 22, 2012). Meda AB (SSE:MEDAA), Solna, Sweden Mission Pharmacal Co....
BioCentury | Nov 4, 2013
Company News

Dara BioSciences, Mission Pharmacal sales and marketing update

...Feb. 18, 2013 & April 30, 2013). Dara Biosciences Inc. (NASDAQ: DARA ), Raleigh, N.C. Mission Pharmacal Co....
BioCentury | Jan 7, 2013
Finance

Buyside View XXI: Sunny side up

...Laboratories Inc. (NASDAQ:DSCO) Surfaxin lucinactant Prevent respiratory distress syndrome in premature infants U.S. EffRx Pharmaceuticals S.A./Mission Pharmacal Co./...
Items per page:
1 - 10 of 17